These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 9675635)

  • 1. Acyclic nucleoside phosphonates in the chemotherapy of DNA virus and retrovirus infections.
    De Clercq E
    Intervirology; 1997; 40(5-6):295-303. PubMed ID: 9675635
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential of acyclic nucleoside phosphonates in the treatment of DNA virus and retrovirus infections.
    De Clercq E
    Expert Rev Anti Infect Ther; 2003 Jun; 1(1):21-43. PubMed ID: 15482100
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections.
    De Clercq E
    Clin Microbiol Rev; 2003 Oct; 16(4):569-96. PubMed ID: 14557287
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemotherapy of the acquired immune deficiency syndrome (AIDS): acyclic nucleoside phosphonate analogues.
    De Clercq E
    Int J Immunopharmacol; 1991; 13 Suppl 1():91-8. PubMed ID: 1823910
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiviral potential of a new generation of acyclic nucleoside phosphonates, the 6-[2-(phosphonomethoxy)alkoxy]-2,4-diaminopyrimidines.
    De Clercq E; Andrei G; Balzarini J; Leyssen P; Naesens L; Neyts J; Pannecouque C; Snoeck R; Ying C; Hocková D; Holý A
    Nucleosides Nucleotides Nucleic Acids; 2005; 24(5-7):331-41. PubMed ID: 16247948
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic potential of Cidofovir (HPMPC, Vistide) for the treatment of DNA virus (i.e. herpes-, papova-, pox- and adenovirus) infections.
    De Clercq E
    Verh K Acad Geneeskd Belg; 1996; 58(1):19-47; discussion 47-9. PubMed ID: 8701600
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic potential of phosphonylmethoxyalkylpurines and -pyrimidines as antiviral agents.
    De Clercq E
    Drugs Exp Clin Res; 1990; 16(7):319-26. PubMed ID: 1965499
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumor potential of acyclic nucleoside phosphonates.
    De Clercq E; Andrei G; Balzarini J; Hatse S; Liekens S; Naesens L; Neyts J; Snoeck R
    Nucleosides Nucleotides; 1999; 18(4-5):759-71. PubMed ID: 10432678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of nucleoside phosphonates and their analogs and prodrugs for inhibition of orthopoxvirus replication.
    Keith KA; Hitchcock MJ; Lee WA; Holý A; Kern ER
    Antimicrob Agents Chemother; 2003 Jul; 47(7):2193-8. PubMed ID: 12821467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanism of action of acyclic nucleoside phosphonates against herpes virus replication.
    Neyts J; De Clercq E
    Biochem Pharmacol; 1994 Jan; 47(1):39-41. PubMed ID: 8311844
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic diversity and antiviral activities of acyclic nucleoside phosphonates.
    Aduma P; Connelly MC; Srinivas RV; Fridland A
    Mol Pharmacol; 1995 Apr; 47(4):816-22. PubMed ID: 7723743
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiretroviral activities of acyclic nucleoside phosphonates [9-(2-phosphonylmethoxyethyl)adenine, 9-(2-phosphonylmethoxyethyl)guanine, (R)-9-(2-phosphonylmethoxypropyl)adenine, and MDL 74,968] in cell cultures and murine sarcoma virus-infected newborn NMRI mice.
    Balzarini J; Vahlenkamp T; Egberink H; Hartmann K; Witvrouw M; Pannecouque C; Casara P; Navé JF; De Clercq E
    Antimicrob Agents Chemother; 1997 Mar; 41(3):611-6. PubMed ID: 9056002
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The potential of acyclic nucleoside phosphonates as broad-spectrum antiviral agents.
    Naesens L; Balzarini J; De Clercq E
    Postepy Biochem; 1995; 41(5 Suppl):347-51. PubMed ID: 8797236
    [No Abstract]   [Full Text] [Related]  

  • 14. Acyclic nucleoside phosphonates: past, present and future. Bridging chemistry to HIV, HBV, HCV, HPV, adeno-, herpes-, and poxvirus infections: the phosphonate bridge.
    De Clercq E
    Biochem Pharmacol; 2007 Apr; 73(7):911-22. PubMed ID: 17045247
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phosphonylmethoxyalkyl purine and pyrimidine derivatives for treatment of opportunistic cytomegalovirus and herpes simplex virus infections in murine AIDS.
    De Castro LM; Kern ER; De Clercq E; Ghaffar A; Mayer EP; Vogt PE; Gangemi JD
    Antiviral Res; 1991 Jul; 16(1):101-14. PubMed ID: 1663726
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of cidofovir in the treatment of DNA virus infections, other than CMV infections, in immunocompromised patients.
    Snoeck R; De Clercq E
    Curr Opin Investig Drugs; 2002 Nov; 3(11):1561-6. PubMed ID: 12476953
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A review of topical and intralesional cidofovir.
    Zabawski EJ
    Dermatol Online J; 2000 Sep; 6(1):3. PubMed ID: 11328613
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of PMPA and PMEA on the kinetics of viral load in simian immunodeficiency virus-infected macaques.
    Silvera P; Racz P; Racz K; Bischofberger N; Crabbs C; Yalley-Ogunro J; Greenhouse J; Jiang JB; Lewis MG
    AIDS Res Hum Retroviruses; 2000 May; 16(8):791-800. PubMed ID: 10826485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acyclic nucleoside phosphonates: a key class of antiviral drugs.
    De Clercq E; Holý A
    Nat Rev Drug Discov; 2005 Nov; 4(11):928-40. PubMed ID: 16264436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro selection of drug-resistant varicella-zoster virus (VZV) mutants (OKA strain): differences between acyclovir and penciclovir?
    Andrei G; De Clercq E; Snoeck R
    Antiviral Res; 2004 Mar; 61(3):181-7. PubMed ID: 15168799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.